Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma
A phase 1/2 trial of Cyclophosphamide, Doxorubicin, Vincristine in hodgkin lymphoma and non-hodgkin lymphoma, run by Evopoint Biosciences Inc., now recruiting.
Overview
Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma is a phase 1/2 interventional study registered as NCT07730515 by Evopoint Biosciences Inc., with 176 participants planned, started 2025-08-15 and due to reach its primary completion in 2028-09-30. Interventions recorded: XNW5004 combined with CHOP (incremental), XNW5004 combined with CHOEP (incremental), XNW5004 combined with CHOP (extended), XNW5004 combined with CHOEP (extended). Conditions listed: Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th
Shares Prednisone, Vincristine, Cyclophosphamide, Doxorubicin.
- TrialTucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Shares Prednisone, Vincristine, Cyclophosphamide, Doxorubicin.
- TrialA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Shares Prednisone, Vincristine, Cyclophosphamide, Doxorubicin.
- TrialA Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Shares Prednisone, Vincristine, Cyclophosphamide, Doxorubicin.
- TrialA Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Shares Prednisone, Cyclophosphamide, Doxorubicin, Non-Hodgkin lymphoma (all types).
- TrialClinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
Shares XNW5004, Evopoint Biosciences.
- TrialA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Shares Prednisone, Vincristine, Cyclophosphamide, Doxorubicin.
- TrialStudy of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
Shares XNW5004, Evopoint Biosciences.